The National Pharmacy Association said chemists have stopped making aspirin available for over the counter sale

In pharmacies across the UK, the shelves where aspirin once stood proud are now eerily bare. Patients, many battling chronic conditions, have found themselves grappling not just with their health, but with the stark reality that a once-ubiquitous medication has become a rare commodity. Reports from the National Pharmacy Association (NPA) reveal that a staggering 86% of pharmacies were unable to supply aspirin to patients from January 13th to 20th, 2026, leading to life-threatening consequences for those in urgent need.

The Spiraling Shortage of Essential Medication

For those suffering from heart conditions, strokes, and diabetes, the lack of aspirin is particularly alarming. According to NPA chair Olivier Picard, “The inability to access aspirin poses a significant risk to patients who rely on this medication for their heart health.” The shortage has forced many chemists to ration supplies, reserving what little they have for patients with the most acute needs—those whose lives may depend on continuity in their medication regimen.

Impact on Patients and Prescribers

Recent findings indicate that over 50.9 million items of aspirin were prescribed in the UK between January and October 2025, making it one of the most frequently dispensed drugs nationally. The sudden scarcity raises questions at the institutional level, as healthcare providers scramble to respond. “Pharmacies that can source aspirin are incurring tremendous costs,” Picard warns. “The NHS reimburses only £2.18 per packet, while the market price has soared to £3.90, leading to an average loss of £1.72 for each packet dispensed.”

• Patients affected: Individuals with histories of strokes and heart diseases, chronic kidney disease, and diabetes.
• Total aspirin prescriptions: Over 50.9 million items prescribed between January-October 2025.
• Cost disparity: Pharmacies lose approximately £1.72 on each packet of aspirin dispensed.

Legislative Barriers and Calls for Reform

The NPA’s concern resonates deeply within the medical community, where experts advocate for urgent legislative reforms. Picard emphasizes, “Current regulations, instituted in 1968, prevent pharmacists from substituting medications. This is not just frustrating for patients; it’s dangerous.” The inability of pharmacists to switch prescriptions or make substitutions when medications are out of stock compromises patient safety and care continuity.

Fiona Loud, Policy Director at Kidney Care UK, elaborates, “Particularly in cases of chronic kidney disease, patients receiving low doses of aspirin face increased risks. If the medication is unavailable, it’s essential that pharmacists have the authority to provide suitable alternatives.” The precedent for such adjustments exists; similar protocols were enacted during the COVID-19 pandemic and after the UK’s exit from the EU, demonstrating that flexibility in healthcare could be both practical and safe.

Economic Implications of the Shortage

The financial strain on pharmacies is exacerbated by soaring medication prices. Data from an internal NPA study indicates that the price of a 75mg packet of dispersible aspirin has skyrocketed from 18p to £3.90 in recent months. “This is not just an issue of accessibility, but also one of sustainability for the pharmacy sector,” Picard adds. “Many independent pharmacies may struggle to survive if these conditions persist.”

The Voice of Patients and Their Safety

Patients have increasingly voiced their frustration over the unavailability of aspirin. One such patient, Margaret Thompson, a 67-year-old widow who was prescribed low-dose aspirin after a mild stroke, said, “It’s terrifying not knowing if I can get my medication when I need it. I feel like my wellbeing is in jeopardy.” Such sentiments reflect a collective uncertainty that extends beyond individual pharmacies, echoing through the corridors of healthcare facilities nationwide.

Experts argue for greater communication from primary care providers to enhance transparency about medication changes. “There needs to be a collaborative effort among pharmacists, doctors, and patients to ensure everyone understands the steps being taken in response to these shortages,” Loud insists.

Seeking Solutions amidst Crisis

In light of the escalating crisis, the NPA is urging government officials to modernize pharmaceutical legislation. The association’s analysis shows that not only do patients suffer, but the very fabric of community pharmacies is at risk. Picard emphasizes, “It is madness to send someone back to their GP for a prescription change when a safe alternative is readily available.”

As communities grapple with the implications of aspirin shortages, the NPA is not merely calling for reform; they’re advocating for systemic change. The healthcare system faces a critical juncture, and how it responds to the current crisis will shape the future of patient safety and pharmacy practice in the UK.

The urgency to act is compounded by the knowledge that many patients who depend on aspirin are facing dire conditions without adequate access to their essential medication. The ripple effects of this shortage are felt not just in pharmacies, but in homes, hospitals, and the endless cycles of care that define the healthcare landscape. As patients continue to navigate their treatment plans amid uncertainty, the entwined fates of policy, practice, and patient wellbeing come into stark relief.

Source: www.cornwalllive.com